Alnylam Files to Begin Phase I Trial of Subcutaneous TTR Drug in UK | GenomeWeb

Alnylam Pharmaceuticals announced this week that it has filed with UK regulators to begin phase I testing of a subcutaneous version of its TTR-mediated amyloidosis treatment called ALN-TTRsc.

Currently, Alnylam is testing an intravenously delivered form of the drug called ALN-TTR02, which it anticipates entering phase III testing by the end of this year. However, the firm has long been planning to incorporate its GalNAc conjugate delivery technology into its TTR amyloidosis program.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: CRISPR-based barcodes to trace cell lineages, and more.

The director of the National Institutes of Health Francis Collins sang the national anthem this week before a baseball game.

French researchers criticize unexpected government plan to cut research funding, ScienceInsider reports.

In Nature this week: genetic mechanism through which some cancers evade the immune system, and more.